Brief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
21/09/2026 14:24
BRIEF-Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model Sept 21 (Reuters) - Recursion Pharmaceuticals, Inc. RXRX.O:
TEMPUS AND RECURSION EXTEND EXISTING DATA LICENSE AGREEMENT AND ENTER NEW LICENSE AGREEMENT FOR RECURSION’S RNA FOUNDATION MODEL
TEMPUS AI, -CO AND RECURSION EXTEND DATA PARTNERSHIP THROUGH NOVEMBER 2029
TEMPUS AI, - RECURSION GRANTS TEMPUS NON-EXCLUSIVE WORLDWIDE LICENSE TO RNA SEQUENCING MODEL TXFM
Source text: ID:nBwr10Lya
Further company coverage: RXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million